Suchergebnisse - "Kelley, Robin Kate"

PubPharm (4)

1

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Song, X. | Kelley, R. | Khan, A. | +12

2

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations : A Phase I Dose-Expansion Study

enthalten in: Cancer discovery | 2022

von Meric-Bernstam, F. | Bahleda, R. | Hierro, C. | +10

3

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma : Randomized Expansion of a Phase I/II Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Kelley, R. | Sangro, B. | Harris, W. | +21

4

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2016

von Papadopoulos, K. | Kelley, R. | Tolcher, A. | +14

1
[1]